Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | TGM2 | P21980 | 6/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.39 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | IDH1 | O75874 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | F13A1 | P00488 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TGM1 | P22735 | 1/20 | 0.36 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25781037 | 0.80 | TGM2 (0.46) | PTPN1PTPN11EGFRTGM2FGFR1 | |
| SCHEMBL17524683 | 0.78 | KDM4C (0.50) | PTPN1PTPN11TGM2FGFR1FGFR4 | |
| SCHEMBL26622957 | 0.78 | TGM2 (0.50) | PTPN1PTPN11EGFRTGM2FGFR4 | |
| SCHEMBL23653144 | 0.75 | PTPN1 (0.47) | PTPN1PTPN11EGFRTGM2FGFR1 | |
| SCHEMBL17522193 | 0.75 | AOC1 (0.44) | PTPN1PTPN11TGM2FGFR1FGFR4 | |
| SCHEMBL25848793 | 0.75 | AOC1 (0.44) | PTPN1PTPN11TGM2FGFR1FGFR4 | |
| SCHEMBL19363848 | 0.73 | HIPK2 (0.45) | PTPN1PTPN11FGFR1FGFR4MAPK3 | |
| SCHEMBL16095414 | 0.73 | PTPN1 (0.48) | PTPN1PTPN11TGM2FGFR1FGFR4 | |
| SCHEMBL28499412 | 0.73 | TDP1 (0.39) | GAAKDM4CLMNA | |
| SCHEMBL21445096 | 0.71 | AOC1 (0.48) | EGFRGAAKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | PTPN1 1734/4885PTPN11 1381/4885EGFR 1297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.